| ²é¿´: 194 | »Ø¸´: 1 | ||
ytfscxlгæ (³õÈëÎÄ̳)
|
[ÇóÖú]
¹ýÃôÐÔ»úÖÆ ¿´²»¶®Á½¶ÎÓ¢Óï Çë´óÏÀ½øÀ´¿´¿´
|
|
1.Eicosanoids£ºA family of lipid mediatorswith diverse biologicalactivities. These metabolitesare the products of thelipoxygenase andcyclooxygenase pathways ¡ªwhich produce leukotrienesand prostaglandins,respectively ¡ª and they areimportant mediators of theallergic inflammatory response. ÕâÊÇÀà¶þÊ®ÍéËáµÄ¼ò½é£¬ËûÊÇÒ»ÖÖ¾ßÓв»Í¬ÉúÎïѧ»îÐÔµÄÖ¬ÖʽéÖʵļÒ×å¡£²»¶®ÖмäÒ»¾ämetaboliteºÍwhich·Ö±ðÖ¸´úʲô£¿ËÄÜ˵³ö¸öÏȺó˳Ðò ˲úÉúʲôȻºóÔõôÁË£¿°×ÈýϩǰÁÐÏÙËØºÍÀà¶þÊ®ÍéËáÓÐɶ¹ØÏµõ¥ÑõºÏøºÍ»·ÑõºÏøͨ··Ö±ð¿ÉÒÔ²úÉú°×ÈýÏ©ºÍǰÁÐÏÙËØ£¬ÕâЩÒò×ÓÊǹýÃôÑ×Ö¢·´Ó¦µÄÖØÒª´«µÝÎï¡£ 2.In this Review, we discuss the evidence for these interacting pathways and describe how the capacity of KIT, and other receptors, to influence Fc¦ÅRI-dependent mast-cell-mediator release might be a function ofthe relative abilities of these receptors to activate these alternative pathways. ÕâÊÇÂÛÎÄÀïµÄabstractÖÐ×îºóÒ»¾ä»° ²»¶®×îºóÒ»¾äµÄÒâ˼ ´Óhow¿ªÊ¼ |
» ²ÂÄãϲ»¶
µ°°×Öʼì²â£º¾«×¼·ÖÎö£¬½âËøÉúÎï·Ö×ÓµÄÃÜÂë
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑé֮СÊóʵÑ飺ÑϽ÷Éè¼Æ£¬½âÎöÉúÃü»úÖÆµÄÖØÒªÔØÌå
ÒѾÓÐ0È˻ظ´
»¯Ñ§¹¤³Ì¼°¹¤Òµ»¯Ñ§ÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ261È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®ÖØ½ðÊô¼ì²â£º¾«×¼É¸²é£¬ÊØ»¤½¡¿µÓë»·¾³µÄ·ÀÏß
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÍܲâÖØ½ðÊôÎÒ±³¹øÈýǧ¡±
ÒѾÓÐ0È˻ظ´
²»ºÏÀíÍÜ¿ÆÑÐʵÑéÖ®¡°ÊóÌÓÈý´ÎÎÒ·¢ÈýƪSCI¡±
ÒѾÓÐ0È˻ظ´
ÄÉÃ×Á£¶È·ÖÎö
ÒѾÓÐ3È˻ظ´
ÁÖ¿ÆÔºÁÖ»¯ËùÕÐÊÕ²ÄÁÏÓ뻯¹¤×¨ÒµË¶Ê¿£¬×ø±êÄϾ©
ÒѾÓÐ0È˻ظ´
Áôѧ--²©Ê¿ÕÐÉú
ÒѾÓÐ15È˻ظ´
»¯Ñ§¹¤³Ì£¬±¾211£¬Çóµ÷¼Á£¬abÇø²»ÏÞ
ÒѾÓÐ4È˻ظ´
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ytfscxl
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 12.3
- Ìû×Ó: 18
- ÔÚÏß: 2.8Сʱ
- ³æºÅ: 2251191
- ×¢²á: 2013-01-20
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
2Â¥2015-03-14 21:24:50













»Ø¸´´ËÂ¥